109 related articles for article (PubMed ID: 17590893)
21. Trastuzumab combined with paclitaxel after doxorubicin and cyclophosphamide for operable HER2-positive breast cancer.
Ferretti G; Felici A; Papaldo P; Carlini P; Fabi A; Cognetti F
Oncologist; 2006 May; 11(5):533; author reply 534. PubMed ID: 16720857
[No Abstract] [Full Text] [Related]
22. [Possibilities and results with Herceptin-Taxol combination in the treatment of breast cancer].
Láng I
Magy Onkol; 2002; 46(2):195-6. PubMed ID: 12202900
[TBL] [Abstract][Full Text] [Related]
23. A meta-analysis of randomized controlled trials comparing chemotherapy plus trastuzumab with chemotherapy alone in HER-2-positive advanced breast cancer.
Liao C; Yin F; Huang P; Cao Y; Gao F
Breast J; 2011; 17(1):109-11. PubMed ID: 21129096
[No Abstract] [Full Text] [Related]
24. Herceptin: from the bench to the clinic.
Colomer R; Shamon LA; Tsai MS; Lupu R
Cancer Invest; 2001; 19(1):49-56. PubMed ID: 11291556
[No Abstract] [Full Text] [Related]
25. [Herceptin (trastuzumab)].
Yamashiro H; Toi M
Gan To Kagaku Ryoho; 2007 Aug; 34(8):1173-6. PubMed ID: 17687197
[TBL] [Abstract][Full Text] [Related]
26. Controversies in the use of adjuvant trastuzumab (Herceptin).
Chowdhury S; Pickering L; Ellis P
J Br Menopause Soc; 2006 Dec; 12(4):172-4. PubMed ID: 17178019
[TBL] [Abstract][Full Text] [Related]
27. HER2 and response to paclitaxel in node-positive breast cancer.
Roukos DH
N Engl J Med; 2008 Jan; 358(2):197; author reply 198. PubMed ID: 18193530
[No Abstract] [Full Text] [Related]
28. Trastuzumab trials steal show at ASCO meeting.
Tuma RS
J Natl Cancer Inst; 2005 Jun; 97(12):870-1. PubMed ID: 15956644
[No Abstract] [Full Text] [Related]
29. Preoperative chemotherapy plus lapatinib or trastuzumab or both in HER2-positive operable breast cancer (CHERLOB Trial).
Guarneri V; Frassoldati A; Piacentini F; Jovic G; Giovannelli S; Oliva C; Conte P
Clin Breast Cancer; 2008 Apr; 8(2):192-4. PubMed ID: 18621618
[No Abstract] [Full Text] [Related]
30. HER2 and response to paclitaxel in node-positive breast cancer.
Ferretti G; Felici A; Cognetti F
N Engl J Med; 2008 Jan; 358(2):197; author reply 198. PubMed ID: 18184969
[No Abstract] [Full Text] [Related]
31. HER2-positive breast cancer: current treatment strategies.
Perez EA; Baweja M
Cancer Invest; 2008 Jul; 26(6):545-52. PubMed ID: 18584344
[No Abstract] [Full Text] [Related]
32. HER2 and response to paclitaxel in node-positive breast cancer.
Nash I
N Engl J Med; 2008 Jan; 358(2):198; author reply 198-9. PubMed ID: 18193532
[No Abstract] [Full Text] [Related]
33. [Rationale for Herceptin in the clinical use].
Ebi H; Sasaki Y
Nihon Rinsho; 2002 Mar; 60(3):463-7. PubMed ID: 11904959
[TBL] [Abstract][Full Text] [Related]
34. Herceptin.
Peyrot J
Oncol Nurs Forum; 1999 Apr; 26(3):515-6. PubMed ID: 10214591
[No Abstract] [Full Text] [Related]
35. Chemotherapy agents in human epidermal growth factor receptor 2-positive breast cancer: time to step out of the limelight.
Lin NU; Winer EP
J Clin Oncol; 2011 Jan; 29(3):251-3. PubMed ID: 21149664
[No Abstract] [Full Text] [Related]
36. Weighing a dose-dense option for adjuvant chemotherapy and trastuzumab in early-stage breast cancer.
Mayer EL; Burstein HJ
J Clin Oncol; 2008 Mar; 26(8):1198-200. PubMed ID: 18323544
[No Abstract] [Full Text] [Related]
37. [Herceptin].
Morginstin T; Shani S; Shemer J
Harefuah; 2000 Mar; 138(6):459-64. PubMed ID: 10883160
[No Abstract] [Full Text] [Related]
38. HER-2 as a target for breast cancer therapy.
Ignatiadis M; Desmedt C; Sotiriou C; de Azambuja E; Piccart M
Clin Cancer Res; 2009 Mar; 15(6):1848-52. PubMed ID: 19289395
[No Abstract] [Full Text] [Related]
39. [Current status and the perspective of treatment strategy for the patients with advanced or recurrent breast cancer].
Kitagawa D; Toi M
Nihon Rinsho; 2007 Jun; 65 Suppl 6():396-401. PubMed ID: 17682183
[No Abstract] [Full Text] [Related]
40. [Herceptin, a monoclonal humanized antibody anti-HER2: a major therapeutic progress in breast cancers overexpressing this oncogene?].
Beuzeboc P; Scholl S; Garau XS; Vincent-Salomon A; Cremoux PD; Couturier J; Palangié T; Pouillart P
Bull Cancer; 1999 Jun; 86(6):544-9. PubMed ID: 10417428
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
